Posted Date: Mar 30, 2020
- Investigator: Kayla J Stallworth
- Type of Study: Drug
The total duration of participation for an individual subject will be up to 120 weeks, including a Screening period of up to 16 weeks (112 days), a double-blind treatment period of 52 weeks, and a further open-label treatment period of 52 weeks. It is anticipated that the study will have an overall duration of at least 40 months, depending on recruitment rate. In addition, subjects who complete the study and receive treatment with LMTM up to and including the last open-label visit may be subsequently offered an opportunity to receive treatment with LMTM in a separate Expanded Access Program (EAP).
Participants Under The Age Of 90 That Are Diagnosed With Either Alzheimer's Disease Or Mild Cognitive Impairment May Qualify.
Alzheimer's Disease, Mild Cognitive Impairment, Neurology
For More Information: